Nasdaq-listed Vivus Inc today entered into a settlement agreement with Dr Reddy’s Laboratories to resolve a long-pending patent litigation related to weight management capsules Qsymia.

According to a statement issued by the US-based drug maker, the litigation, pending since 2015, resulted from the submission of an abbreviated new drug application (Anda) by Dr Reddy’s seeking approval to market generic versions of Qsymia.

The settlement permits the drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances.